Clinical question:What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?/Table

From Cancer Guidelines Wiki

Back to content

Table - Summary of five randomised trials comparing neoadjuvant chemotherapy with surgery alone

Author Name N/n Age ECOG Sx% NACT/Sx Regime Adjuvant Treatment CT Response rates (%) Survival HR, 95% CI Survival stage II
Scagliotti 2012[1] CHEST 270/ 127 62 (37-80) 0,1 88/84 Gemcitabine /Cisplatin x 3 Nil 35.4 0.63, (0.43-0.92)

p=0.02

NR
Pisters 2010[2] S9900 354/NR 65 (35-83) 0,1 98/90 Paclitaxel/ Carboplatin x 3 Nil 41 0.79, (0.6-1.6)

p=0.11

NR
Felip 2010[3] NATCH 624/144 64 (36-89) 0,1,2 91/96 Paclitaxel/ Carboplatin x 3 *Paclitaxel Carboplatin x 3 53.3 0.88, (0.69-1.12)

p=0.31

0.88, (0.69-1.12)

p=0.31

Gilligan 2007 [4] LU22 519/ 163 61 (33-76) 0,1,2 91/93 Platinum based x 3 Nil 49 1.02, 0.81-1.13

p=0.86

NR
Depierre 2002[5] FTCG 355/57 61 (37-73) 0,1,2 97/93 MIC x 2 MIC x 2 64 NS

p=0.9

NS
Key

NR: Not reported

N/n: Total number of subjects on trial / Number of patients with stage II

MIC: Mitomycin, Ifosfamide, Cisplatin

CT: Chemotherapy

Sx %: Percentage of patients who underwent surgery in the Neoadjuvant chemotherapy arm (NACT) compared with surgery arm (S)

* Separate arm with adjuvant chemotherapy

References

  1. Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, et al. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. J Clin Oncol 2012 Jan 10;30(2):172-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22124104.
  2. .
  3. .
  4. .
  5. .